Overcoming the Round Window Barrier: A Critical Review of Nanocomposite In-Situ Gels for Inner Ear Therapy

The escalating global prevalence of inner ear disorders, particularly Sensorineural Hearing Loss (SNHL) and Meniere’s Disease (MD), presents a critical public health challenge, with over 430 million people affected worldwide. Current pharmacotherapies are severely limited by anatomical barriers: the Blood-Labyrinth Barrier (BLB) blocks systemic drug delivery (>99% drug exclusion), while standard intratympanic injections fail due to rapid drainage via the Eustachian tube (<20 minutes retention). This "drainage paradox" necessitates frequent, painful injections, compromising efficacy, patient compliance, and safety. To overcome these hurdles, in situ gelling systems represent a transformative advancement. These formulations transition from a low-viscosity liquid in situ to a gel depot upon contact with the middle ear, adhering to the Round Window Membrane (RWM). This innovation extends drug residence time from minutes to 24–48 hours (standard gels) or 7–14 days for cutting-edge nanocomposite gels. The latter employs a "Trojan Horse" strategy, utilising drug-loaded nanoparticles (e.g., PLGA, liposomes) engineered to penetrate the RWM via endocytic pathways, dramatically enhancing bioavailability and enabling sustained release. Nanocomposite gels deliver therapeutics for diverse applications: rescuing hair cells in Sudden SNHL, regulating endolymphatic pressure in MD, shielding against chemotherapy-induced ototoxicity, alleviating tinnitus, and facilitating inner ear gene therapy with biologics (e.g., siRNA, growth factors). Rigorous evaluation of sol-gel transition temperature, syringeability, rheology, ex vivo drug release, mucoadhesion, and ototoxicity testing ensures safety and performance. Despite promising preclinical data, clinical translation faces challenges, including sterilisation complications (without compromising gel integrity), potential pH alterations from polymer degradation, and regulatory scrutiny. The failure of OTO-104 (a Poloxamer-based gel) in Phase 3 trials highlights the need for robust clinical endpoints that mitigate high placebo responses in neurotology. Future directions prioritise theranostic gels integrating diagnostic agents (e, g., MRI contrast) for real-time placement verification and refining manufacturing. If these hurdles are resolved, in situ gelling systems hold immense potential to revolutionise inner ear therapy, shifting from inefficient injections to precise, patient-friendly, sustained treatment.